Peijia Medical Achieves 28% Market Share in China's TAVR Market, DCwire Gains FDA Approval

According to company disclosures, Peijia Medical's TAVR implant volume surged 37% year-over-year in the first half of 2026, reaching over 2,800 cases, with its TaurusTrio aortic valve system capturing 28% market share in China's transfemoral TAVI segment. The TaurusTrio, launched in December 2024 as China's first dedicated aortic regurgitation device, has already been deployed across 200+ hospitals with over 200 implants, accounting for more than 30% of Peijia's total TAVR procedures.

Meanwhile, Peijia's DCwire microcatheter received FDA 510(k) clearance in March 2026, marking the first FDA approval for a domestically-developed neural intervention microcatheter. Additionally, Chairman and CEO Zhang Yi has increased shareholding by 4.554 million shares, worth over 250 million Hong Kong dollars, since December 2025.